Vaxart, Inc. (VXRT) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1162386,
    "name": "Vaxart, Inc.",
    "stock_name": "Vaxart, Inc.",
    "full_name": "Vaxart, Inc.",
    "name_url": "stocks-analysis/vaxart-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "0.37",
    "chg": -0.01,
    "chgp": "-2.32%",
    "dir": -1,
    "prev_price": "0.38",
    "mcapval": "88.13",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US92243A2006",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.46 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vaxart-inc-1162386-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Vaxart, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vaxart-inc-technically-bullish-or-bearish-3547832",
        "imagepath": "",
        "date": "2025-09-20 20:04:01",
        "description": "As of 8 September 2025, the technical trend for Vaxart, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend and weekly KST showing bearish momentum. However, the weekly and monthly MACD readings are mildly bullish, suggesting some potential for upward movement. The Bollinger Bands also reflect a mildly bearish outlook on both weekly and monthly time frames. \n\nIn terms of performance, Vaxart's returns have significantly underperformed the S&P 500 across multiple periods, with a year-to-date decline of 41.85% compared to the S&P's gain of 12.22%, and a one-year return of -57.23% versus the S&P's 17.14%...."
      },
      {
        "title": "Is Vaxart, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vaxart-inc-overvalued-or-undervalued-3544078",
        "imagepath": "",
        "date": "2025-09-20 18:37:04",
        "description": "As of 3 August 2023, the valuation grade for Vaxart, Inc. has moved from does not qualify to risky. The company is currently overvalued based on its financial metrics. Key ratios include a Price to Book Value of 2.03, an EV to Sales ratio of 1.22, and a troubling ROCE of -535.64%. \n\nIn comparison to peers, Vaxart's EV to EBITDA ratio stands at -1.09, while TScan Therapeutics, Inc. has a ratio of 0.5157, and Prelude Therapeutics, Inc. has a ratio of -0.0018, indicating Vaxart is underperforming relative to its industry counterparts. The stock has significantly lagged behind the S&P 500, with a year-to-date return of -41.85% compared to the index's 12.22%, highlighting its challenging position in the market...."
      }
    ],
    "total": 7,
    "sid": "1162386",
    "stock_news_url": "https://www.marketsmojo.com/news/vaxart-inc-1162386"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Vaxart, Inc. technically bullish or bearish?

2025-09-20 20:04:01

As of 8 September 2025, the technical trend for Vaxart, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend and weekly KST showing bearish momentum. However, the weekly and monthly MACD readings are mildly bullish, suggesting some potential for upward movement. The Bollinger Bands also reflect a mildly bearish outlook on both weekly and monthly time frames. In terms of performance, Vaxart's returns have significantly underperformed the S&P 500 across multiple periods, with a year-to-date decline of 41.85% compared to the S&P's gain of 12.22%, and a one-year return of -57.23% versus the S&P's 17.14%....

Is Vaxart, Inc. overvalued or undervalued?

2025-09-20 18:37:04

As of 3 August 2023, the valuation grade for Vaxart, Inc. has moved from does not qualify to risky. The company is currently overvalued based on its financial metrics. Key ratios include a Price to Book Value of 2.03, an EV to Sales ratio of 1.22, and a troubling ROCE of -535.64%. In comparison to peers, Vaxart's EV to EBITDA ratio stands at -1.09, while TScan Therapeutics, Inc. has a ratio of 0.5157, and Prelude Therapeutics, Inc. has a ratio of -0.0018, indicating Vaxart is underperforming relative to its industry counterparts. The stock has significantly lagged behind the S&P 500, with a year-to-date return of -41.85% compared to the index's 12.22%, highlighting its challenging position in the market....

View All News